Background-Aspirin for the primary prevention of coronary heart disease (CHD) is only recommended for individuals at high risk for CHD although the majority of CHD events occur in individuals who are at low to intermediate risk. Methods and Results-To estimate the potential of coronary artery calcium (CAC) scoring to guide aspirin use for primary prevention of CHD, we studied 4229 participants from the Multi-Ethnic Study of Atherosclerosis who were not on aspirin at baseline and were free of diabetes mellitus. Using data from median 7.6-year follow-up, 5-year number-needed-totreat estimations were calculated by applying an 18% relative CHD reduction to the observed event rates. This was contrasted to 5-year number-needed-to-harm estimations based on the risk of major bleeding reported in an aspirin metaanalysis. Results were stratified by a 10% 10-year CHD Framingham Risk Score (FRS). Individuals with CAC≥100 had an estimated net benefit with aspirin regardless of their traditional risk status (estimated 5-year number needed to treat of 173 for individuals <10% FRS and 92 for individuals ≥10% FRS, estimated 5-year number needed to harm of 442 for a major bleed). Conversely, individuals with zero CAC had unfavorable estimations (estimated 5-year number needed to treat of 2036 for individuals <10% FRS and 808 for individuals ≥10% FRS, estimated 5-year number needed to harm of 442 for a major bleed). Sex-specific and age-stratified analyses showed similar results. Conclusions-For the primary prevention of CHD, Multi-Ethnic Study of Atherosclerosis participants with CAC≥100 had favorable risk/benefit estimations for aspirin use while participants with zero CAC were estimated to receive net harm from aspirin. (Circ Cardiovasc Qual Outcomes. 2014;7:453-460.)
T he current role of aspirin in the primary prevention of cardiovascular disease (CVD) is limited to use only in individuals at elevated risk for a cardiovascular event, thus withholding aspirin from lower risk patients who represent the majority of the primary prevention population and in whom a large proportion of cardiovascular events occur. 1 When tested for primary prevention in clinical trials of predominantly lowrisk individuals, aspirin has been shown to decrease the rate of CVD events but at a near-equivalent risk of increased bleeding. [2] [3] [4] [5] For primary prevention, more liberal use of aspirin would include treatment of individuals at low risk for CVD, resulting in a small absolute benefit that is likely to be outweighed by the increase in bleeding associated with aspirin use. Conversely, limiting aspirin use to only high-risk individuals negates the opportunity to prevent a significant number of cardiovascular events, many of which present as unheralded myocardial infarction or sudden cardiac death. 6, 7 Therefore, there is much interest in improving assessment of CVD risk to identify individuals with the most favorable risk/benefit profiles. Coronary artery calcium (CAC) score is a highly specific marker of the atherosclerotic plaque burden in the coronary arteries. There is a nearly 10-fold higher risk of coronary heart disease (CHD) events in patients with substantially elevated CAC. 8 In addition, a CAC score of zero has been shown to be a powerful predictor of a favorable prognosis, even in the presence of traditional risk factors. 9, 10 These strong associations give CAC the ability to improve discrimination and provide a significant improvement in net risk reclassification. 8, 11, 12 The goal of this analysis, using data from the Multi-Ethnic Study of Atherosclerosis (MESA), is to evaluate if risk stratification with CAC could guide the use of aspirin therapy, potentially focusing treatment on more individuals at high risk and therefore more likely to prevent a CVD event while avoiding aspirin in individuals who are truly at low risk in whom aspirin risk exceeds benefit.
Methods

Study Design and Participants
MESA is a longitudinal epidemiological study of 6814 multiethnic men and women 45 to 84 years old initiated in July 2000 to evaluate the prevalence, progression, and clinical significance of subclinical atherosclerosis. Complete details of the design and recruitment strategy of MESA have been previously published. 13 In summary, between July 2000 and September 2002, MESA enrolled participants at 6 US field centers (New York, Baltimore, St. Paul, Chicago, Los Angeles, and Forsyth County, North Carolina). Communities with significant ethnic diversity were targeted for recruitment, and participants who identified themselves as white, black, Hispanic, or Chinese and were free of known clinical CVD at baseline were enrolled. The study protocol was reviewed and approved by the institutional review board at the participating institutions. Each participant gave informed consent for the study. Of the 6814 MESA participants included in the baseline examination, we excluded participants with diabetes mellitus at the time of baseline examination (n=880), defined as a fasting glucose level of ≥126 mg/dL or use of hypoglycemic medications. We excluded individuals with diabetes mellitus because of the consideration of diabetes mellitus as a CHD risk equivalent as well as the 2 recent randomized trials in individuals with diabetes mellitus that did not show a reduction in CVD events with aspirin use. 14, 15 Participants using aspirin (n=978) or with missing aspirin data (n=227) at the time of the baseline examination were also excluded. Aspirin use was defined as any aspirin dose taken 3 or more times per week. Additionally, 5 MESA participants were missing outcomes data, and 495 were missing covariates, thus 4229 participants were included in our sample. A flowchart of participants included in the study is shown in Figure 1 .
Procedures
The scanning and interpretation methods for cardiac computed tomography (CT) in MESA have been previously reported. 16 CAC scores were determined with chest CT using either a cardiac-gated electron-beam CT scanner (Los Angeles, Baltimore, and New York) or a multidetector CT system (Chicago, St. Paul, and Forsyth County). All patients were scanned twice, and CAC (Agatston) scores were averaged. A cardiologist or radiologist interpreted all scans at the MESA CT reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center). Agreement for the presence of CAC was high (κ statistic 0.92), and the intraclass correlation coefficient for the Agatston score between readers was 0.99. Clinical teams at each of the 6 centers performed a baseline examination including assessment of standard CVD risk factors. Blood for basic laboratory assessment was obtained and processed at each of the 6 centers and analyzed at the central MESA laboratory (University of Vermont, Burlington, VT). New occurrences of CVD and CHD events were documented over a median follow-up of 7.6 years. Participants or their family members were contacted via telephone interview every 9 to 12 months and questioned about interim admissions to the hospital, outpatient diagnoses of CHD or CVD, and deaths. Medical records were successfully obtained in 98% of hospital admissions and 95% of outpatient cardiovascular diagnoses. Two physicians from the MESA mortality and morbidity review committee independently reviewed and classified each event. The full committee adjudicated if there was disagreement between the 2 physicians.
Outcomes
The cardiovascular benefits of aspirin in clinical trials have mostly been limited to a reduction in myocardial infarction and stroke. [17] [18] [19] [20] [21] [22] Therefore, the potential benefit of aspirin therapy was applied to only hard CHD and CVD events. Hard CHD events included nonfatal myocardial infarction, resuscitated cardiac arrest, and CHD death. Hard CVD events included hard CHD events plus nonfatal and fatal stroke. Transient ischemic attack was not included.
Statistical Analysis
Baseline characteristics of participants included in the study were analyzed after stratification for baseline aspirin use. Frequencies and proportions were calculated for categorical variables. For continuous variables, means with standard deviations are presented. We used Kaplan-Meier estimates of cumulative event-free survival to describe
WHAT IS KNOWN
• In individuals without known cardiovascular disease, daily aspirin has been associated with a reduction in cardiovascular events and a small, but significant, increase in risk of bleeding.Coronary artery calcium testing provides a measure of plaque in the coronary arteries and is therefore a promising risk assessment tool, though it is unclear how this test should be used in clinical practice.
WHAT THE STUDY ADDS
• The benefits and risks of daily aspirin were estimated according to coronary artery calcium scores in individuals without known cardiovascular disease who participated in the Multi-Ethnic Study of Atherosclerosis study. • Multi-Ethnic Study of Atherosclerosis participants with significant plaque in their arteries (coronary artery calcium score≥100) were estimated to be 2× to 4× more likely to prevent a heart attack with aspirin use than to have a major bleed secondary to aspirin, and these results were independent of qualification for aspirin by American Heart Association guidelines. • Conversely, Multi-Ethnic Study of Atherosclerosis participants with no calcified plaque (coronary artery calcium score=0) were estimated to be 2× to 4× more likely to suffer a major bleed from aspirin use than to prevent a heart attack with aspirin, and these results were also independent of qualification for aspirin by American Heart Association guidelines. the occurrence of hard CHD and CVD events over time. Absolute event rates for both CHD and CVD were analyzed in patients stratified by baseline CAC score (0, 1-99, ≥100), and Cox multivariable hazard ratios were determined for each CAC stratum. Models were adjusted for age, sex, race/ethnicity, MESA site, cigarette smoking status, cigarette pack-years, body mass index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, lipid-lowering medication, hypertension, antihypertensive medication, family history of myocardial infarction, education level, and Framingham risk score (FRS). The proportional hazards assumption of the Cox model was confirmed by the inspection of log-negative log survival curves and an interaction term between the CAC score groups and time. Given the exclusion of ≈10% of participants because of missing variables, we performed an additional Cox model with imputation for participants with missing variables. These results did not significantly differ from the results of the primary analysis (results not shown). To determine the estimated risk/benefit profiles of aspirin therapy, we performed 2 separate analyses, one based on the total sample and another based on a sex-specific analysis. A prior meta-analysis found an 18% reduction in CHD events with aspirin use independent of sex. 1 This risk reduction has been used in other studies analyzing the use of aspirin. 23 We applied this relative risk reduction in CHD to both sexes stratified by CAC scores and a 10% 10-year CHD risk threshold calculated using the FRS. For the sex-specific analysis, we calculated absolute hard CHD event rates in men and hard CVD event rates in women after stratification by baseline CAC score. An estimated aspirin benefit of a 32% reduction in CHD for men and a 17% reduction in CVD for women, as stated in the United State Preventive Service Task Force (USPSTF) guidelines, 24 was applied to the absolute MESA event rate in each CAC stratum. Using the reciprocal of the absolute risk reduction, a number needed to treat at a median follow-up of 7.6 years was calculated. To contrast the potential cardiovascular benefit with the potential bleeding risk, the direct number needed to treat was adjusted to a 5-year number needed to treat (NNT 5 ), using the method of Altman-Anderson 25 and contrasted with the 5-year number needed to harm (NNH 5 ). The NNH 5 was calculated using the reciprocal of the absolute risk increase on aspirin based on the absolute increase in the rate of major bleeding seen in a sex-specific aspirin meta-analysis. 2 The major bleeding rate for both sexes combined was increased by a rate of 0.23% at 5 years; therefore, the estimated NNH 5 was 442 for a major bleed. The sex-specific major bleeding rate with aspirin was increased by a rate of 0.26% at 5 years in men and by a rate of 0.20% in women; therefore, the estimated NNH 5 was 388 for a major bleed in men and 512 for a major bleed in women. For the sex analysis, men and women were stratified based on the threshold for qualification for aspirin therapy by current American Heart Association (AHA) guidelines, including a >10-year 10% CHD risk for men and a >10-year 10% CVD risk for women. 26, 27 FRSs were used for CHD and CVD risk estimations. 28, 29 As a sensitivity analysis, we performed an agestratified analysis, analyzing the sample in 3 separate age categories including both sexes and assuming an 18% reduction in CHD. The absolute increase in bleeding for the 3 age categories was based on the major bleeding rate for both sexes combined (0.23% at 5 years in a study population with a mean age of 56 8] years) and USPSTF guidelines that assume, compared with 45-to 59-year-old adults, a 3-fold and 4.5-fold increase in bleeding in individuals aged 60 to 69 and 70 to 79 years old, respectively. Finally, we calculated the relative risk reduction with aspirin that would be required for aspirin to have a net benefit (NNT 5 > NNH 5 ) in individuals with zero CAC in our sample. We also calculated the absolute increase in bleeding that would have to be present for individuals with CAC≥100 to have an estimated net harm (NNH 5 < NNH 5 ) with aspirin use. All statistical analyses were performed with SAS v9.2 (SAS, Cary, NC).
Results
Compared with MESA participants taking aspirin at baseline, the 4229 participants not on aspirin were younger (mean age 60.6±10.2 years versus 66.2±9.2), more often nonwhite, and had fewer cardiovascular risk factors with a mean 10-year FRS of 7.4% compared with a FRS of 10.3% in those participants using aspirin at baseline (Table 1) . Of the participants included in this analysis, 2361 (55.8%) had a CAC score of zero, 1093 (25.8%) had a score of 1 to 99, and 775 (18.3%) had a score of ≥100. The frequency of CHD and CVD events, event rates per 1000 person-years, and hazard ratios for MESA participants stratified by CAC score are shown in Table 2 . Compared with participants with a CAC score of zero, those with CAC≥100 had over a 9-fold higher risk for a CHD event and over a 6-fold higher risk for a CVD event.
After adjusting for traditional risk factors, CAC scores were still significantly associated with CHD and CVD events (hard CHD hazard ratio=4. 19 2.36-7 .43] and hard CVD hazard ratio=2.85 1.81-4.50] for participants with CAC≥100 compared with those with CAC=0). The 5-year hard CHD event rates, estimated NNT 5 , and estimated NNH 5 with aspirin use in MESA participants assuming an 18% relative reduction in CHD and an absolute increase in bleeding rate of 0.23% at 5 years with aspirin for both sexes are shown in Table 3 . Individuals with CAC≥100 had an estimated net benefit with aspirin regardless of their traditional CHD risk status (estimated NNT 5 of 173 for individuals <10% FRS and 92 for individuals ≥10% FRS, estimated NNH 5 of 442 for a major bleed). Conversely, individuals with zero CAC had unfavorable estimations (estimated NNT 5 of 2036 for individuals <10% FRS and 808 for individuals ≥10% FRS, estimated NNH 5 of 442 for a major bleed). The results of the sex-specific analysis are shown in Tables 4 and 5 . MESA men with a CAC score of ≥100 had favorable risk/benefit profiles for aspirin regardless of qualification by AHA guidelines (>10% 10-year CHD risk), with an estimated NNT 5 of 49 and 56 to prevent a CHD event for aspirin qualifiers and nonqualifiers, respectively, compared with an estimated NNH 5 of 388 for a major bleed. Conversely, men with a CAC score of zero had unfavorable estimated risk/benefit profiles, with a NNT 5 to prevent a hard CHD event of 1389 for aspirin nonqualifying men and 571 for aspirin qualifying men (estimated NNH 5 388). Based on CVD risk, MESA women with CAC≥100 had favorable risk/benefit profiles with aspirin therapy regardless of aspirin qualification (>10% 10-year CVD risk), with an estimated NNT 5 of 126 and 122 for aspirin qualifiers and nonqualifiers women, respectively, compared with an estimated NNH 5 of 512. However, the risk/benefit profile for women with zero CAC varied based on aspirin qualification (estimated NNT 5 253 and 1322 for aspirin qualifying and nonqualifying women, respectively, estimated NNH 5 512). Figure 2 displays the estimated NNT 5 values for men and women included in the analysis in reference to the estimated NNH 5 values. An age-stratified analysis showed similar results across 3 age categories though, for MESA participants with CAC≥100, younger individuals had more favorable estimations because of a lower bleeding risk (Table 6 ). Finally, a sensitivity analysis looking at the effect of different CHD risk reductions and varying bleeding rates on NNT 5 and NNH 5 estimations is shown in Table 7 . Assuming the rate of major bleeding used in the primary analysis (0.23% over 5 years), for individuals with CAC zero in this sample to have an estimated net benefit with aspirin (NNT 5 > NNH 5 ), aspirin would have to produce a 64% relative risk reduction for hard CHD events. Assuming an 18% reduction in CHD, for individuals with CAC≥100 in this sample to have a net harm with aspirin (NNT 5 < NNH 5 ), the absolute bleeding rate would have to increase by a rate of 0.9% over 5 years with aspirin use, a 3.5-fold higher rate of major bleeding compared with rate seen in the meta-analysis used for this study.
Discussion
The results of our study demonstrate that, for the primary prevention of CVD, MESA participants with CAC≥100 have an estimated net treatment benefit on aspirin while participants with a CAC score of zero have unfavorable risk/benefit profiles with aspirin. Both of these findings are independent of CHD risk based on traditional risk factors. In a sex-specific analysis, we estimated that both men and women with CAC≥100 would benefit from aspirin regardless of qualification for aspirin by AHA guidelines. For MESA men with zero CAC, we estimated a net harm with aspirin use, including in men who qualify for aspirin by AHA guidelines. Results for women varied according to baseline CVD risk as low-risk Table 3 
. Estimated Number Needed to Treat and Number Needed to Harm With Use of Aspirin in MESA Participants Stratified by 10-Year CHD Risk and Baseline CAC Assuming an 18% Reduction in CHD in Both Sexes
CHD Risk
No. of Participants MESA women with zero CAC were estimated to have a net harm with aspirin use while women at elevated global CVD risk were estimated to receive a net benefit from aspirin regardless of the presence of CAC. In our study sample, over 10% of men and women who would not qualify for aspirin by AHA guidelines had CAC≥100. Additionally, over 30% of MESA participants who would qualify for aspirin by AHA guidelines have zero CAC. The latter patients would have an estimated net harm with aspirin use, as the risk of an aspirininduced major bleed was estimated to be 2-fold higher than the likelihood of aspirin preventing a CHD event. An agestratified analysis showed similar results across 3 age strata though older individuals with CAC≥100 did not have as favorable of estimations because of their increased risk of bleeding. Our study is not the first to raise the question of the use of CAC to estimate benefit from preventive cardiovascular therapy. Screening for CAC may be useful in determining the need for statin therapy as well. A recent analysis of MESA participants with an elevated high-sensitivity C-reactive protein who could have qualified for Justification for the Use of Statins in Prevention: an Interventional Trial Evaluating Rosuvastatin (JUPITER) 30 showed that CAC provided excellent risk stratification in this statin-eligible population. 31 JUPITER-eligible MESA participants with a CAC score≥100 had markedly higher event rates compared with JUPITEReligible MESA participants with a CAC score of zero. Applying the risk reduction seen with rosuvastatin in the JUPITER trial to the JUPITER-eligible MESA participants produced vastly different estimated absolute benefits depending on the baseline CAC score, with an estimated NNT 5 to prevent a CHD event of 549 for participants with zero CAC compared with a NNT 5 of 24 for patients with CAC≥100. 31 These findings, combined with the results of our analysis, suggest that CAC may be useful in determining the potential benefit of both aspirin and statin therapy, thus increasing the use of CAC as a tool for improved clinical decision making. The cost of a CAC score is ≈$100 and is currently not covered by most insurance companies. Concern has been raised that CAC scoring may be used to generate motivation for additional testing (stress testing and angiography) and as well as further imaging for incidental findings though prior research has suggested that there is potential cost savings downstream for those identified with zero CAC, as they are less likely to undergo additional testing. 32 CAC is associated with radiation exposure. The measured dose of radiation in MESA was equivalent to bilateral mammography (0.89 mSv) although modern scanners frequently perform scans with a delivered dose of ≈0.5 mSv. Concern has also been raised that CAC testing may be associated with unfavorable psychological or behavioral effects such as increased anxiety in those with elevated CAC or less motivation to follow healthy lifestyle behaviors in those with zero CAC. These concerns lend further support to repeated calls for randomized data on the effect of CAC scoring on patient and physician behavior as well as hard CVD outcomes. [33] [34] [35] . Current screening guidelines do not recommend CAC testing in low-risk patients. 36 However, a recent analysis of 44 052 asymptomatic people showed that individuals with no cardiovascular risk factors but elevated CAC had higher mortality rates than individuals with multiple risk factors but zero CAC, suggesting that exclusive use of traditional risk factors to determine preventive therapy may not be the optimal approach to CVD prevention. 37 The relatively low prevalence of CAC scores≥100 in low-risk participants raises questions about cost-effectiveness. However, the importance of a finding of zero CAC, and possibly avoiding costs of bleeding that may result from aspirin therapy, must also be considered. The absence of CAC is associated with a low risk of CHD, CVD, and all-cause mortality. 10, 38 Patients with zero CAC could potentially be reassured that they are making the correct clinical choice in deferring preventive pharmacotherapy. In our study, 74% of participants had either a CAC score of 0 or CAC≥100, suggesting the majority of individuals could obtain useful information from the test. The remainder of individuals had CAC scores in the range of 1 to 99. These individuals, while at greater CHD risk than those with zero CAC, did not have definitive risk/benefit profiles. To determine the use of aspirin in these individuals, patient preference may play a larger role, and consideration must also be given to clinical equivalence as many patients may be more willing to experience a bleeding event as opposed to suffering a heart attack. There are several limitations to this study. The necessary exclusion of patients on aspirin at baseline created a lower risk study population compared with the overall MESA cohort, and thus, the cardiovascular event rates may be underestimated compared with a typical middle-aged population. The ideal approach to address this study's hypothesis would be a randomized controlled trial. However, conducting such a trial for a diagnostic screening test in the setting of primary prevention requires a large sample size, long duration, and high cost. 39 The 18% CHD reduction for the total sample, 32% reduction in CHD for men, and 17% reduction in CVD for women are larger benefits than what the recent meta-analyses of aspirin in primary prevention have shown. 4, 5 However, we chose to use the treatment benefits for aspirin estimated by the USPSTF guidelines because the MESA sample is more similar to the samples of the first 6 randomized aspirin trials [17] [18] [19] [20] [21] [22] as opposed to the 3 recent trials 14, 15, 40 that focused on patients with diabetes mellitus and peripheral arterial disease (we excluded individuals with diabetes mellitus and <1% of our population had peripheral arterial disease). Although we attempted to account for differences in bleeding rates in each sex and across separate age groups, the estimated increased risk of bleeding on aspirin applied to each of these strata was fixed despite that bleeding risk is known to vary by other risk factors. 2 A recent large prospective cohort suggested that the incidence of major bleeding in the general population might be higher than the rates seen in randomized trials, 41 and a recent meta-analysis used nontrivial bleeding as an outcome and found a significantly higher rate of increased rate of bleeding (0.76% at 5 years) on aspirin. 5 Therefore, our estimated number needed to treat and number needed to harm calculations should be regarded as hypothesis generating. Nevertheless, it would take significant variations in the cardiovascular event rates, the estimated treatment benefits, or the estimated bleeding risks to negate the concept that individuals with zero CAC have an unfavorable risk/benefit profile on aspirin while those CAC score≥100 should have a net benefit. In conclusion, for individuals who could be treated with aspirin for the primary prevention of CVD, MESA participants with CAC≥100 had favorable risk/benefit estimations for aspirin use while participants with zero CAC were estimated to receive net harm from aspirin. These results were independent of CHD risk calculated by traditional methods. 
